Short answer
GERON CORP (GERN) filed an 8-K current report with the SEC on February 25, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1) dated Feb 25, 2026.
GERON CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1) dated Feb 25, 2026
- Actual figures: revenue, expenses, cash position, contained in Exhibit 99.1; review required for specific metrics
- GERN is a clinical-stage biopharma; results likely reflect RYTELO (imetelstat) commercial launch trajectory, a key investor focus
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GERON CORP 8-K filings
Get the next GERN 8-K as it lands
Follow GERN for push alerts, or ask the research agent what this filing means.